Multi‐centre experience on the use of perhexiline in chronic heart failure and refractory angina: old drug, new hope

The objective of this study is to report on our 5‐year collective experience on the use of perhexiline in the UK, in patients with chronic heart failure (CHF) and/or refractory angina with respect to ‘real‐life’ drug side effects and toxicity, therapeutic drug level monitoring, 5 year mortality outcomes and predictors of response to perhexiline therapy.

[1]  M. Frenneaux,et al.  The heart metabolism: pathophysiological aspects in ischaemia and heart failure. , 2009, Current pharmaceutical design.

[2]  L. Opie,et al.  Metabolic mechanisms in heart failure. , 2007, Circulation.

[3]  R. Shah,et al.  Can pharmacogenetics help rescue drugs withdrawn from the market? , 2006, Pharmacogenomics.

[4]  O. Alfieri,et al.  A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. , 2006, Journal of the American College of Cardiology.

[5]  Robert G Weiss,et al.  Is the failing heart energy starved? On using chemical energy to support cardiac function. , 2004, Circulation research.

[6]  G. Francis,et al.  Heart failure therapy at a crossroad: are there limits to the neurohormonal model? , 2003, Journal of the American College of Cardiology.

[7]  L. Campeau.  The Canadian Cardiovascular Society grading of angina pectoris revisited 30 years later. , 2002, The Canadian journal of cardiology.

[8]  G. Radda,et al.  Increased uncoupling proteins and decreased efficiency in palmitate-perfused hyperthyroid rat heart. , 2001, American journal of physiology. Heart and circulatory physiology.

[9]  T. Myrmel,et al.  Myocardial substrate metabolism influences left ventricular energetics in vivo. , 2000, American journal of physiology. Heart and circulatory physiology.

[10]  S. Vatner,et al.  Progressive loss of myocardial ATP due to a loss of total purines during the development of heart failure in dogs: a compensatory role for the parallel loss of creatine. , 1999, Circulation.

[11]  J. Ingwall,et al.  Creatine kinase system in failing and nonfailing human myocardium. , 1996, Circulation.

[12]  T. Inubushi,et al.  Quantitative measurements of cardiac phosphorus metabolites in coronary artery disease by 31P magnetic resonance spectroscopy. , 1995, Circulation.

[13]  L. Wing,et al.  Is perhexiline essential for the optimal management of angina pectoris? , 1995, Australian and New Zealand journal of medicine.

[14]  C. Malloy,et al.  Direct Evidence That Perhexiline Modifies Myocardial Substrate Utilization from Fatty Acids to Lactate , 1995, Journal of cardiovascular pharmacology.

[15]  M. Relling,et al.  Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans. , 1993, The Journal of clinical investigation.

[16]  J. Horowitz,et al.  Perhexiline maleate treatment for severe angina pectoris--correlations with pharmacokinetics. , 1986, International journal of cardiology.

[17]  S. Sherlock,et al.  Impaired oxidation of debrisoquine in patients with perhexiline liver injury. , 1984, Gut.

[18]  J. Horowitz,et al.  Liver disease induced by perhexiline maleate. , 1981, The Medical journal of Australia.

[19]  P. Bouche,et al.  Perhexiline maleate and peripheral neuropathy , 1979, Neurology.

[20]  G. Lagier,et al.  [Hypoglycemia in 2 patients treated with perhexiline maleate]. , 1977, La Nouvelle presse medicale.

[21]  S. Fisch.  Medical treatment of angina pectoris. , 1966, Modern treatment.

[22]  S. Silver,et al.  Heart Failure , 1937, The New England journal of medicine.

[23]  Simon Stewart,et al.  Prognosis of patients with heart failure compared with common types of cancer. , 2003, Heart failure monitor.

[24]  H. Krum,et al.  Systematic Review of the Efficacy and Safety of Perhexiline in the Treatment of Ischemic Heart Disease , 2001, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[25]  D. Laplane,et al.  Polyneuropathy during perhexiline maleate therapy. , 1981, International journal of neurology.